BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Onyx Pharmaceuticals and Bayer Drug Trial Fails]]>http://www.bloggingstocks.com/2010/06/14/Bayer-onyx-pharmaceuticals-trial-fails/http://www.bloggingstocks.com/2010/06/14/Bayer-onyx-pharmaceuticals-trial-fails/http://www.bloggingstocks.com/2010/06/14/Bayer-onyx-pharmaceuticals-trial-fails/#commentsFiled under:

Bayer and Onyx Pharmaceuticals (ONXX) announced Monday morning that a Phase III study of lung cancer treatment Nexavar did not meet its primary endpoint -- improving overall survival. The two pharmaceutical firms said they were "disappointed" with the failure of the trial and that they will evaluate the findings to see if the data may have any impact on other Nexavar trials.

This trial was measuring Nexavar plus the standard treatment chemotherapy drugs against the chemo drugs alone in patients with newly diagnosed non-small cell lung cancer. Non-small cell lung cancer comprises roughly 85% to 90% of diagnosed lung cancers. Nexavar is already used to treat kidney and liver cancer.

Continue reading Onyx Pharmaceuticals and Bayer Drug Trial Fails

Onyx Pharmaceuticals and Bayer Drug Trial Fails originally appeared on BloggingStocks on Mon, 14 Jun 2010 09:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>BayerBayer AGdrug trialsinthenewsNexavarONXXOnyx PharmaceuticalsMon, 14 Jun 2010 09:30:00 EST<![CDATA[Onyx Pharmaceuticals is finding new ways to treat cancer]]>http://www.bloggingstocks.com/2008/01/04/onyx-pharmaceuticals-is-finding-new-ways-to-treat-cancer/http://www.bloggingstocks.com/2008/01/04/onyx-pharmaceuticals-is-finding-new-ways-to-treat-cancer/http://www.bloggingstocks.com/2008/01/04/onyx-pharmaceuticals-is-finding-new-ways-to-treat-cancer/#commentsFiled under:

The market's continued choppiness/consolidating pattern does not mean there aren't growth stocks out there for high-risk investors, and Onyx Pharmaceuticals is one pharmaceutical company that fits the bill.

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) specializes in small molecule technology, a new, promising method that blocks cancer-causing mechanisms in the human body. In collaboration with Bayer Pharmaceuticals, the company develops and markets compounds that inhibit the function, or modulate the activity of the RAS signaling pathway to treat cancer and other diseases.

Analysts believe ONXX's cancer drug Nexaver as a treatment for advanced kidney cancer could be a big winner, with the company gaining FDA approval for the drug in 2005. ONXX is also testing the drug as a possible treatment for other kinds of cancer (liver, skin, and lung cancer). The Reuters F2007/F2008 EPS consensus estimates for ONXX are -$0.52 to $0.97.

Continue reading Onyx Pharmaceuticals is finding new ways to treat cancer

Onyx Pharmaceuticals is finding new ways to treat cancer originally appeared on BloggingStocks on Fri, 04 Jan 2008 18:39:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>cancercancer treamentshealth careONXXOnyx Pharmaceuticalspharmaceutical sectorFri, 04 Jan 2008 18:39:00 EST<![CDATA[IPO & secondary preview -- Week of June 18, 2007]]>http://www.bloggingstocks.com/2007/06/19/ipo-and-secondary-preview-week-of-june-18-2007/http://www.bloggingstocks.com/2007/06/19/ipo-and-secondary-preview-week-of-june-18-2007/http://www.bloggingstocks.com/2007/06/19/ipo-and-secondary-preview-week-of-june-18-2007/#commentsFiled under: , , ,

Wall Street's equity market offers a modest plate this week, with three IPOs and four Secondaries on the docket.

Those deals tentatively scheduled to price include:

IPOs:

Tuesday

  • Aldabra 2 Acquisition (ALL.U), a 30M-share IPO for this business finance company. Lazard is the lead manager. Filing price: $10.00
  • Sterlite Industries (SLT), a 125M-share IPO for this India-based metals company. Merrill Lynch, Morgan Stanley and Citigroup are the lead managers. Filing price: $13.85.

Thursday

  • Care Investment Trust (CRE), an 18.75M-share IPO for this business finance company. Credit Suisse and Merrill Lynch are the lead managers. Filing range: $15.00-$17.00.

Continue reading IPO & secondary preview -- Week of June 18, 2007

IPO & secondary preview -- Week of June 18, 2007 originally appeared on BloggingStocks on Tue, 19 Jun 2007 08:19:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>ACASAIMCAldabra 2 AcquisitionAldabra2AcquisitionALL>UAltra HoldingsAltraHoldingsAmerican Capital StrategiesAmerican Physicians Service GroupAmericanCapitalStrategiesAmericanPhysiciansServiceGroupAMPHCare Investment TrustCareInvestmentTrustCREONXXOnyx PharmaceuticalsOnyxPharmaceuticalsSLTSterlite IndustriesSterliteIndustriesTue, 19 Jun 2007 08:19:00 EST<![CDATA[Analyst initiations 11-1-06: CommVault initiated by four firms]]>http://www.bloggingstocks.com/2006/11/01/analyst-initiations-11-1-06-commvault-initiated-by-four-firms/http://www.bloggingstocks.com/2006/11/01/analyst-initiations-11-1-06-commvault-initiated-by-four-firms/http://www.bloggingstocks.com/2006/11/01/analyst-initiations-11-1-06-commvault-initiated-by-four-firms/#commentsFiled under: ,

MOST NOTEWORTHY: Onyx Pharmaceuticals (ONXX) and CommVault (CVLT) top the list of today's initiations.

  • Citigroup started Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) with a Hold rating and $22 target as the broker expects shares to be range bound until clarity is given into the company's cancer indications. A bunch firms initiated recent IPO CommVault Systems this morning, including IPO managers First Boston and Goldman Sachs.
  • Goldman started shares of CommVault Systems, Inc. (NASDAQ:CVLT) with a Buy and $21 target, and added shares to its prestigious Conviction Buy List, as they expect the company to benefit from relationships with DELL and HDS. First Boston is more lukewarm on the name, starting shares with a Neutral rating and the same target of $21. Other firms' imitating the stock this morning was Merrill Lynch with a Buy, and Thomas Weisel and RBC Capital with Outperform ratings.

OTHER INITIATIONS:

  • Caris initiated three retail names this morning: American Eagle Outfitters, Inc. (NASDAQ:AEOS), Limited Brands, Inc. (NYSE:LTD) and Men's Wearhouse, Inc. (NYSE:MW). The broker favors Limited and Men's Wearhouse with Above Average ratings, thinking inventory and cost management can bring margin expansion. Caris is less excited about American Eagle, starting shares with an Average rating, believing shares are fairly valued at current levels.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

Analyst initiations 11-1-06: CommVault initiated by four firms originally appeared on BloggingStocks on Wed, 01 Nov 2006 13:05:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>aeosamerican eagleAmericanEaglecommvaultcvltlimited brandsLimitedBrandsltdmemen's warehouseMen'sWarehouseonxxonyx pharmaceuticalsOnyxPharmaceuticalsWed, 01 Nov 2006 13:05:00 EST